Drug Trial Radar · NCT05003804
Allergic Disease Onset Prevention Study
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
283
Actual
Start
Sep 1, 2021
Primary completion
Nov 26, 2024
Study completion Oct 21, 2025
Sponsor
- Lead sponsor
- Siolta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 days, up to 14 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subjects will be enrolled in a three-part sequential approach. Participants in the safety-run portion of the study (Part A1: 1 year to \<6 years of age and A2: 1 month to \<12 months of age) will receive 28 days of treatment with STMC-103H or placebo, followed by 28 days of follow-up. A Data and Safety Monitoring Committee (DSMC) will review safety data after all patients in each part complete 28 days of therapy prior to enrolling the next part. After A2, Part B will enroll 224 patients for 336 days of treatment with STMC-103H or placebo, followed by 336 days of follow-up. Stool, blood, and optional samples will be collected in Parts A2 and part B. Primary safety endpoints are frequency, type and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as findings on physical exams, vitals, and safety laboratories. The primary efficacy endpoint is incidence of physician-diagnosed atopic dermatitis at day 336.
Conditions
- Atopic Dermatitis
- Type 1 Hypersensitivity
Interventions
STMC-103HBiological
STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
PlaceboBiological
Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A1 and A2: Assess safety and tolerability of STMC-103H in children and infants at risk for development of allergic disease by assessing adverse events (AE), serious adverse events (SAE), and AEs of special interestTime frame: Through 56 days of study
- Part B: Assess the safety, tolerability of STMC-103H in neonate and infants subjects at risk for development of atopic disease by monitoring AEs, SAEs, AESI, physical exam findings, and clinical safety laboratories.Time frame: Through 672 days of study
- Part B: Primary Efficacy Endpoint: Incidence of physician-diagnosed atopic dermatitis at 336 daysTime frame: Day 336
Locations
31 sites in 3 countries. Site status is shown where the registry gives one.
University of Arizona Health Sciences
Tucson, Arizona
Arkansas Children's Research Institute
Little Rock, Arkansas
UCLA Health
Los Angeles, California
Rady Children's Hospital - San Diego
San Diego, California
UCSF Benioff Children's Hospital
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Children's Healthcare of Atlanta
Atlanta, Georgia
Lurie Children's Hospital
Chicago, Illinois
University of Chicago Medicine
Chicago, Illinois
Riley Children's Health at University of Indiana
Indianapolis, Indiana
Johns Hopkins University School of Medicine
Baltimore, MD, Maryland
Boston Children's Hospital
Boston, Massachusetts
University of Michigan Health
Ann Arbor, Michigan
Northwell Healthcare
Great Neck, New York
NYU Langone Fink Children's
New York, New York
Mt. Sinai Jaffe Allergy Institute
New York, New York
University of Rochester Medical Center
Rochester, New York
Cincinnati Children's Hospital
Cincinnati, Ohio
Tribe Clinical Research
Greenville, South Carolina
Coastal Pediatrics Research
Summerville, South Carolina
Dell Medical School at UT Austin
Austin, Texas
UT Southwestern/Children's Health
Dallas, Texas
Seattle Allergy and Asthma Research Institute
Seattle, Washington
Univ. of Wisconsin-Madison/Jackson Research Group
Madison, Wisconsin
The Children's Hospital at Westmead
Westmead, New South Wales, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
The Women's and Children's Hospital
Adelaide, South Australia, Australia
Monash Children's Hospital
Clayton, Victoria, Australia
Murdoch Children's Research Institute
Parkville, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Centro de Neumologia Pediatrica
Caguas, Puerto Rico, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.